Correction to: Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With HIV: Outcomes in Real-world Setting With and Without Tenofovir Resistance
Clinical Infectious Diseases · 13.08.2026
DOI: 10.1093/cid/ciag488 ↗Kurz gefasst
Korrektur in der Zeitschrift Clinical Infectious Diseases, online erschienen am 13.08.2026.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Correction to: Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With HIV: Outcomes in Real-world Setting With and Without Tenofovir Resistance. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag488
Vancouver
Correction to: Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With HIV: Outcomes in Real-world Setting With and Without Tenofovir Resistance. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag488
BibTeX
@article{euvimed2026,
title = {Correction to: Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With HIV: Outcomes in Real-world Setting With and Without Tenofovir Resistance},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag488}
}
EUVIMED